Kenneth M. Verburg

10.6k total citations · 3 hit papers
93 papers, 8.2k citations indexed

About

Kenneth M. Verburg is a scholar working on Pharmacology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Kenneth M. Verburg has authored 93 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pharmacology, 25 papers in Surgery and 23 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Kenneth M. Verburg's work include Inflammatory mediators and NSAID effects (54 papers), Osteoarthritis Treatment and Mechanisms (20 papers) and Anesthesia and Pain Management (15 papers). Kenneth M. Verburg is often cited by papers focused on Inflammatory mediators and NSAID effects (54 papers), Osteoarthritis Treatment and Mechanisms (20 papers) and Anesthesia and Pain Management (15 papers). Kenneth M. Verburg collaborates with scholars based in United States, United Kingdom and France. Kenneth M. Verburg's co-authors include Gilbert Geis, Andrew Whelton, Lee S. Simon, J B Lefkowith, Jeffrey D. Kent, Jay L. Goldstein, Fred E. Silverstein, Gerald A. Faich, Mark T. Brown and Aimee Burr and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Kenneth M. Verburg

92 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis

2000 2.4k citations Fred E. Silverstein, Gerald A. Faich et al. JAMA profile →
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

2005 808 citations Nancy A. Nussmeier, Andrew Whelton et al. New England Journal of Medicine profile →
Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis

1999 636 citations Lee S. Simon, Richard C. Hubbard et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth M. Verburg United States	37	5.5k	2.1k	1.9k	1.3k	1.1k	93	8.2k
James A. Bolognese United States	31	3.3k 0.6×	1.3k 0.6×	1.1k 0.6×	798 0.6×	472 0.4×	71	5.7k
Barry J. Gertz United States	37	1.9k 0.3×	1.0k 0.5×	820 0.4×	294 0.2×	1.2k 1.1×	69	5.9k
Francesco Cipollone Italy	50	1.7k 0.3×	1.5k 0.7×	1.6k 0.9×	187 0.1×	854 0.8×	194	8.1k
Franco Cuccurullo Italy	52	940 0.2×	1.8k 0.8×	2.6k 1.4×	274 0.2×	985 0.9×	193	9.1k
M. Michael Wolfe United States	42	1.8k 0.3×	3.0k 1.4×	347 0.2×	259 0.2×	560 0.5×	138	7.0k
Rolf M. Nüsing Germany	40	1.6k 0.3×	445 0.2×	558 0.3×	118 0.1×	1.1k 1.0×	116	5.1k
Takeshi Sugaya Japan	61	929 0.2×	1.5k 0.7×	2.9k 1.5×	156 0.1×	821 0.8×	229	10.7k
Masakazu Haneda Japan	67	960 0.2×	2.7k 1.3×	2.4k 1.3×	270 0.2×	2.3k 2.1×	292	16.1k
Giorgio Sesti Italy	67	942 0.2×	3.4k 1.6×	2.7k 1.4×	308 0.2×	2.8k 2.7×	416	15.1k
Ulrich Kintscher Germany	48	733 0.1×	1.5k 0.7×	2.6k 1.3×	301 0.2×	1.8k 1.7×	170	9.3k

Countries citing papers authored by Kenneth M. Verburg

Since Specialization

Citations

This map shows the geographic impact of Kenneth M. Verburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth M. Verburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth M. Verburg more than expected).

Fields of papers citing papers by Kenneth M. Verburg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth M. Verburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth M. Verburg. The network helps show where Kenneth M. Verburg may publish in the future.

Co-authorship network of co-authors of Kenneth M. Verburg

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth M. Verburg. A scholar is included among the top collaborators of Kenneth M. Verburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth M. Verburg. Kenneth M. Verburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Colloca, Luana, Robert H. Dworkin, John T. Farrar, et al.. (2023). Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials. Clinical Pharmacology & Therapeutics. 113(4). 878–886. 9 indexed citations

Neogi, Tuhina, David J. Hunter, Melvin Churchill, et al.. (2022). Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Research & Therapy. 24(1). 78–78. 17 indexed citations

Mont, Michael A., John A. Carrino, Mary Anne Nemeth, et al.. (2021). Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study. Surgical Technology Online. 38. 467–477. 2 indexed citations

Mont, Michael A., John A. Carrino, Aimee Burr, et al.. (2020). Postoperative outcome of patients who underwent total joint replacement during the tanezumab phase 3 osteoarthritis development program: a 24-week observational study. Osteoarthritis and Cartilage. 28. S29–S29. 1 indexed citations

Brown, M., Martin Koltzenburg, Há Thi Nguyen, Christine R. West, & Kenneth M. Verburg. (2015). Tanezumab Does Not Cause Sympathetic Nervous System Dysfunction in Clinical Osteoarthritis Studies (P3.303). Neurology. 84(14_supplement). 7 indexed citations

Schnitzer, Thomas J., Evan F. Ekman, Egilius L.H. Spierings, et al.. (2014). Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Annals of the Rheumatic Diseases. 74(6). 1202–1211. 123 indexed citations

Apfelbaum, Jeffrey L., Paul J. Desjardins, Mark T. Brown, & Kenneth M. Verburg. (2008). Multiple-day Efficacy of Parecoxib Sodium Treatment in Postoperative Bunionectomy Pain. Clinical Journal of Pain. 24(9). 784–792. 24 indexed citations

Snabes, Michael C., et al.. (2007). Parecoxib sodium administered over several days reduces pain after gynecologic surgery via laparotomy. Journal of Clinical Anesthesia. 19(6). 448–455. 12 indexed citations

Pollak, Richard, Richard M. Jay, Howard J. Hillstrom, et al.. (2006). Analgesic Efficacy of Valdecoxib for Acute Postoperative Pain After Bunionectomy. Journal of the American Podiatric Medical Association. 96(5). 393–407. 24 indexed citations

10.

Nussmeier, Nancy A., Andrew Whelton, Mark T. Brown, et al.. (2006). Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery. Anesthesiology. 104(3). 518–526. 116 indexed citations

11.

Nussmeier, Nancy A., Andrew Whelton, Mark T. Brown, et al.. (2005). Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. New England Journal of Medicine. 352(11). 1081–1091. 808 indexed citations breakdown →

12.

Petri, Michelle, et al.. (2004). Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis.. PubMed. 31(8). 1614–20. 36 indexed citations

13.

Daniels, Stephen E., Paul J. Desjardins, Sheela Talwalker, David P. Recker, & Kenneth M. Verburg. (2002). The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. The Journal of the American Dental Association. 133(5). 611–621. 99 indexed citations

14.

Fricke, James R., et al.. (2002). Valdecoxib Is More Efficacious Than Rofecoxib in Relieving Pain Associated With Oral Surgery. American Journal of Therapeutics. 9(2). 89–97. 67 indexed citations

15.

Goldstein, Jay L., Kaffa Fakouhi, William W. Zhao, et al.. (2001). Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: A multicenter trial. Gastroenterology. 120(5). A597–A597. 7 indexed citations

16.

Silverstein, Fred E., Gerald A. Faich, Jay L. Goldstein, et al.. (2000). Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. JAMA. 284(10). 1247–1247. 2401 indexed citations breakdown →

17.

Goldstein, Jay L., Fred E. Silverstein, Naurang M. Agrawal, et al.. (2000). Reduced Risk of Upper Gastrointestinal Ulcer Complications With Celecoxib, A Novel Cox-2 Inhibitor. The American Journal of Gastroenterology. 95(7). 1681–1690. 232 indexed citations

18.

Henry, D P, Ronald R. Bowsher, & Kenneth M. Verburg. (1991). Session 1: Radioenzymatic Assay for Histamine: Development and Validation. Scandinavian Journal of Gastroenterology. 26(sup180). 26–31. 4 indexed citations

19.

Villarreal, Daniel, Ronald H. Freeman, James O. Davis, Kenneth M. Verburg, & Richard C. Vari. (1986). Renal mechanisms for suppression of renin secretion by atrial natriuretic factor.. Hypertension. 8(6_pt_2). 41 indexed citations

20.

Verburg, Kenneth M. & D P Henry. (1984). Binding of histamine by glass surfaces. Inflammation Research. 14(5-6). 633–636. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact